M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example - XML Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
: M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example

Page standards status: Informative
Raw xml | Download

<Composition xmlns="http://hl7.org/fhir">
  <id value="568060"/>
  <meta>
    <versionId value="5"/>
    <lastUpdated value="2026-06-22T14:51:09.037Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/m11-report-section-03"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="additional"/>
    <div xml:lang="en" xmlns="http://www.w3.org/1999/xhtml" lang="en"/>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-description">
    <valueMarkdown value="Example of M11ReportSection03 Profile"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
        <code value="active"/>
        <display value="Active"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <url value="https://fevir.net/resources/Composition/568060"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="568060"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <status value="final"/>
  <type>
    <coding>
      <system value="http://loinc.org"/>
      <code value="35528-9"/>
      <display value="Clinical trial protocol Clinical trial protocol"/>
    </coding>
    <text value="CeSHarP Report"/>
  </type>
  <category>
    <coding>
      <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
      <code value="C218526"/>
      <display
               value="ICH M11 Protocol Section 3 TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS"/>
    </coding>
    <text value="section3-estimands"/>
  </category>
  <subject>🔗 
    <reference value="ResearchStudy/267245"/>
    <type value="ResearchStudy"/>
    <display
             value="A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example"/>
  </subject>
  <date value="2026-06-22T14:51:09.037Z"/>
  <author>
    <display value="Brian S. Alper, MD, MSPH"/>
  </author>
  <title
         value="M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example"/>
  <custodian>🔗 
    <reference value="Organization/118079"/>
    <type value="Organization"/>
    <display value="Computable Publishing LLC"/>
  </custodian>
  <relatesTo>
    <type value="derived-from"/>
    <targetReference>🔗 
      <reference value="ResearchStudy/267245"/>
      <type value="ResearchStudy"/>
      <display
               value="A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example"/>
    </targetReference>
  </relatesTo>
  <relatesTo>
    <type value="cite-as"/>
    <targetMarkdown
                    value="M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 568060. Revised 2026-06-22. Available at: https://fevir.net/resources/Composition/568060. Computable resource at: https://fevir.net/resources/Composition/568060#json."/>
  </relatesTo>
  <section>
    <title value="3 TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS"/>
    <code>
      <coding>
        <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
        <code value="C218526"/>
        <display
                 value="ICH M11 Protocol Section 3 TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS"/>
      </coding>
      <text value="section3-estimands"/>
    </code>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <section>
      <title value="3.1 Primary Objective(s) and Associated Estimand(s)"/>
      <code>
        <coding>
          <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
          <code value="C218527"/>
          <display
                   value="ICH M11 Protocol Section 3.1 Primary Objective(s) and Associated Estimand(s)"/>
        </coding>
        <text value="3.1-Primary-Objective(s)-and-Associated-Estimand(s)"/>
      </code>
      <text>
        <status value="empty"/>
        <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
      </text>
      <section>
        <title value="3.1.1 Primary Objective 1"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218528"/>
            <display
                     value="ICH M11 Protocol Section 3.1.1 Primary Objective"/>
          </coding>
        </code>
        <focus>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-primaryOutcome-0"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)"/>
        </focus>
        <text>
          <status value="additional"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><p>Primary objective label: Treatment success</p><p>Primary objective description:To demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the proportion of patients achieving treatment success from insulin-induced hypoglycemia using a non-inferiority margin of 10%</p><table><tbody><tr><th>Type</th><th>Primary</th></tr><tr><td>Population</td><td>Study Population.</td></tr><tr><td>Treatment</td><td>Glucagon Nasal Powder (Experimental)</td></tr><tr><td>Treatment</td><td>Glucagon Hydrochloride Solution (Active Comparator)</td></tr><tr><td>Endpoint</td><td><p>Proportion achieving treatment success</p><p>Endpoint title: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)</p><p>Outcome description: The proportion of patients achieving treatment success defined as either an increase in PG to &gt;70 mg/dL or an increase of &gt;20 mg/dL from nadir within 30 minutes after administration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration.</p></td></tr><tr><td>Population-level Summary</td><td>risk difference</td></tr></tbody></table></div>
        </text>
        <entry>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-primaryOutcome-0"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)"/>
        </entry>
        <entry>🔗 
          <reference value="Group/267506"/>
          <type value="Group"/>
          <display value="M11 IGBJ Protocol Example Eligibility Criteria"/>
        </entry>
        <entry>🔗 
          <reference value="Group/370701"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder (Experimental)"/>
        </entry>
        <entry>🔗 
          <reference value="Group/370702"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution (Active Comparator)"/>
        </entry>
      </section>
    </section>
    <section>
      <title value="3.2 Secondary Objective(s) and Associated Estimand(s)"/>
      <code>
        <coding>
          <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
          <code value="C218529"/>
          <display
                   value="ICH M11 Protocol Section 3.2 Secondary Objective(s) and Associated Estimand(s)"/>
        </coding>
        <text value="3.2-Secondary-Objective(s)-and-Associated-Estimand(s)"/>
      </code>
      <text>
        <status value="additional"/>
        <div xmlns="http://www.w3.org/1999/xhtml"/>
      </text>
      <section>
        <title value="3.2.1 Secondary Objective 1"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218530"/>
            <display
                     value="ICH M11 Protocol Section 3.2.1 Secondary Objective"/>
          </coding>
        </code>
        <focus>
          <display value="serious adverse events (SAEs)"/>
        </focus>
        <text>
          <status value="additional"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><p>Secondary objective label: Safety and tolerability</p><p>Secondary objective description: To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG</p><table><tbody><tr><th>Estimand Characteristic</th><th>Description</th></tr><tr><td>Endpoint</td><td><p>serious adverse events (SAEs)</p></td></tr></tbody></table></div>
        </text>
        <entry>
          <display value="serious adverse events (SAEs)"/>
        </entry>
      </section>
      <section>
        <title value="3.2.1 Secondary Objective 2"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218530"/>
            <display
                     value="ICH M11 Protocol Section 3.2.1 Secondary Objective"/>
          </coding>
        </code>
        <focus>
          <display value="treatment-emergent adverse events (TEAEs)"/>
        </focus>
        <text>
          <status value="additional"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><p>Secondary objective label: Safety and tolerability</p><p>Secondary objective description: To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG</p><table><tbody><tr><th>Estimand Characteristic</th><th>Description</th></tr><tr><td>Endpoint</td><td><p>treatment-emergent adverse events (TEAEs)</p><p>Outcome description: treatment-emergent adverse events (TEAEs) (including gastrointestinal, nasal, and non-nasal AEs)</p></td></tr></tbody></table></div>
        </text>
        <entry>
          <display value="treatment-emergent adverse events (TEAEs)"/>
        </entry>
      </section>
      <section>
        <title value="3.2.1 Secondary Objective 3"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218530"/>
            <display
                     value="ICH M11 Protocol Section 3.2.1 Secondary Objective"/>
          </coding>
        </code>
        <focus>
          <display value="vital signs"/>
        </focus>
        <text>
          <status value="generated"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><table><tbody><tr><th>Estimand Characteristic</th><th>Description</th></tr><tr><td>Endpoint</td><td><p>vital signs</p></td></tr></tbody></table></div>
        </text>
        <entry>
          <display value="vital signs"/>
        </entry>
      </section>
      <section>
        <title value="3.2.1 Secondary Objective 4"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218530"/>
            <display
                     value="ICH M11 Protocol Section 3.2.1 Secondary Objective"/>
          </coding>
        </code>
        <focus>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-0"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)"/>
        </focus>
        <text>
          <status value="additional"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><p>Secondary objective label: To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG</p><p>Secondary objective description: PK parameters include AUC, Cmax, Tmax PD parameters include BGmax and Tmax</p><table><tbody><tr><th>Estimand Characteristic</th><th>Description</th></tr><tr><td>Endpoint</td><td><p>Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)</p></td></tr></tbody></table></div>
        </text>
        <entry>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-0"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)"/>
        </entry>
      </section>
      <section>
        <title value="3.2.1 Secondary Objective 5"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218530"/>
            <display
                     value="ICH M11 Protocol Section 3.2.1 Secondary Objective"/>
          </coding>
        </code>
        <focus>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-1"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)"/>
        </focus>
        <text>
          <status value="generated"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><table><tbody><tr><th>Estimand Characteristic</th><th>Description</th></tr><tr><td>Endpoint</td><td><p>PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)</p></td></tr></tbody></table></div>
        </text>
        <entry>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-1"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)"/>
        </entry>
      </section>
      <section>
        <title value="3.2.1 Secondary Objective 6"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218530"/>
            <display
                     value="ICH M11 Protocol Section 3.2.1 Secondary Objective"/>
          </coding>
        </code>
        <focus>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-2"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)"/>
        </focus>
        <text>
          <status value="additional"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><p>Secondary objective label: To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG</p><p>Secondary objective description: PK parameters include AUC, Cmax, Tmax PD parameters include BGmax and Tmax</p><table><tbody><tr><th>Estimand Characteristic</th><th>Description</th></tr><tr><td>Endpoint</td><td><p>Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)</p></td></tr></tbody></table></div>
        </text>
        <entry>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-2"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)"/>
        </entry>
      </section>
      <section>
        <title value="3.2.1 Secondary Objective 7"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218530"/>
            <display
                     value="ICH M11 Protocol Section 3.2.1 Secondary Objective"/>
          </coding>
        </code>
        <focus>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-3"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)"/>
        </focus>
        <text>
          <status value="additional"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><p>Secondary objective label: To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG</p><p>Secondary objective description: PK parameters include AUC, Cmax, Tmax PD parameters include BGmax and Tmax</p><table><tbody><tr><th>Estimand Characteristic</th><th>Description</th></tr><tr><td>Endpoint</td><td><p>PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)</p></td></tr></tbody></table></div>
        </text>
        <entry>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-3"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)"/>
        </entry>
      </section>
      <section>
        <title value="3.2.1 Secondary Objective 8"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218530"/>
            <display
                     value="ICH M11 Protocol Section 3.2.1 Secondary Objective"/>
          </coding>
        </code>
        <focus>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-4"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)"/>
        </focus>
        <text>
          <status value="additional"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><p>Secondary objective label: To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG</p><p>Secondary objective description: PK parameters include AUC, Cmax, Tmax PD parameters include BGmax and Tmax</p><table><tbody><tr><th>Estimand Characteristic</th><th>Description</th></tr><tr><td>Endpoint</td><td><p>PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)</p></td></tr></tbody></table></div>
        </text>
        <entry>
          <type value="EvidenceVariable"/>
          <identifier>
            <type>
              <text value="FEvIR Linking Identifier"/>
            </type>
            <system value="https://fevir.net/FLI"/>
            <value value="NCT03421379-secondaryOutcome-4"/>
            <assigner>
              <display value="Computable Publishing LLC"/>
            </assigner>
          </identifier>
          <display
                   value="PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)"/>
        </entry>
      </section>
    </section>
    <section>
      <title value="3.3 Exploratory Objective(s)"/>
      <code>
        <coding>
          <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
          <code value="C218531"/>
          <display
                   value="ICH M11 Protocol Section 3.3 Exploratory Objective(s)"/>
        </coding>
        <text value="3.3-Exploratory-Objective(s)"/>
      </code>
      <text>
        <status value="additional"/>
        <div xmlns="http://www.w3.org/1999/xhtml"/>
      </text>
      <section>
        <title value="3.3.1 Exploratory Objective 1"/>
        <code>
          <coding>
            <system
                    value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
            <code value="C218532"/>
            <display
                     value="ICH M11 Protocol Section 3.3.1 Exploratory Objective"/>
          </coding>
        </code>
        <focus>
          <display value="Presence of anti-glucagon antibodies"/>
        </focus>
        <text>
          <status value="additional"/>
          <div xmlns="http://www.w3.org/1999/xhtml"><div><p>   </p>
</div>
<div><strong>Exploratory Objectives</strong>
    <p><strong>Description </strong>Explore the formation of anti-glucagon antibodies to glucagon</p>
    <p><strong>Outcome Measures:</strong></p>
    <p><strong>Unnamed outcome measure</strong></p>
    <table>
        <tbody>
            <tr>
                <td><strong>Endpoint</strong></td>
                <td>Presence of anti-glucagon antibodies</td>
            </tr>
        </tbody>
    </table><p>      </p>
    <p><strong>Name: </strong>To evaluate the recovery from clinical symptoms of hypoglycemia</p>
    <p><strong>Description </strong>Hypoglycemia symptoms questionnaire</p></div></div>
        </text>
        <entry>
          <display value="Presence of anti-glucagon antibodies"/>
        </entry>
      </section>
    </section>
  </section>
</Composition>